Bone Cancer

"...a comprehensive description of bone tumors from basic to clinical aspects by the most recent data available...specifically useful to medical students and scientists, health professionals, researchers and teachers working in the osteo-articular field." --Anticancer Research

"Reviewing the current advances in the progression and therapeutic approaches to bone cancer is an extremely challenging task. Bone cancer is not a single disease; rather, it is a field comprising a diverse and complex range of malignancies, from primary bone tumors of stromal cell origin, to hematopoietic malignancies and secondary metastatic bone disease. Dominique Heymann has assembled an exciting, comprehensive and up-to-date series of reviews contributed by experts in the basic and clinical aspects of bone research. In the past decade, our understanding of cancers involving bone has increased tremendously, underpinned by advances in the cellular, molecular and biochemical mechanisms of bone cell interactions in health and disease, together with advances in genetics, diagnostics, imaging and therapeutic strategies. All these aspects are covered in this timely volume, which will galvanize further cooperative efforts in the coming years between basic researchers, oncologists and pathologists towards understanding the causes of different bone cancers and translating this knowledge into the clinic." --Agi E. Grigoriadis, PhD, Departments of Craniofacial Development and Orthodontics, King's College London, United Kingdom

"Our understanding of bone biology and diseases has strikingly progressed in the last decade. In parallel, the processes that lead to various forms of cancer have been further unraveled and the mechanisms leading to metastatic spread further explored. In this book, Dr. Heymann has gathered some of the world experts on these subjects to explore the cutting edge where these fields merge in the context of bone cancer and metastasis, their pathophysiology, diagnosis and treatment. This encompassing book will undoubtedly meet the needs of residents and fellows as well as expert clinicians and scientists." --Roland Baron, Professor, Harvard Medical School, Boston MA, USA

Dominique Heymann studied cell biology, biochemistry and immunology in INSERM (French NIH) unit 211 at the University of Nantes and received his Ph.D. in 1995. He was appointed Associate Professor in 2001 in the Department of Histology and Embryology. In 2009, he was awarded a personal Chair of Histology and Embryology.

Currently he is the Quality Control Manager of the Tissue Bank and Gene and Cellular Therapy Unit at Nantes Hospital. He heads a laboratory research group (INSERM UMR 957) of 65 people at the Faculty of Medicine, where the pathogenesis of primary bone tumours, and more specifically, the role of bone microenvironment (osteoclasts, mesenchymal stem cells, OPG/RANK/RANKL, IL-6 and MCSF cytokine family) in tumour growth is studied.

In 2006, Dominique Heymann won the Paul Mathieu prize from the National Academy of Medicine for his work entitled "From the osteolytic process associated to primary bone tumors to the development of bi-therapies for osteosarcoma. He was on the national scientific advisory board of INSERM (2008-2012) and is now Co-Chairman of INSERM scientific commission n5 ("Physiology and pathophysiology of endocrine, bone, skin and gastrointestinal tissues). He has authored approximately 180 publications in peer- reviewed journals, more than 300 abstracts and 20 book chapters. He is also Associate Editor of Life Sciences, Academic Editor of PLoS ONE, Editor-in-Chief of the Open Bone Journal and serves on the Editorial Board of Current Medicine Chemistry, European Journal of Pharmacology, and Journal of Bone Oncology.

Section 1: Bone Microenvironment and Bone Cancer Section 2: Markers of Bone Cancer (cells, genes and proteins) Section 3: Primary Bone Tumors Section 4: Technical Aspects Section 5: Nervous System in Bone Cancer Section 6: Bone Metastases